• LAST PRICE
    3.2200
  • TODAY'S CHANGE (%)
    Trending Up0.0500 (1.5773%)
  • Bid / Lots
    2.8500/ 2
  • Ask / Lots
    5.0700/ 2
  • Open / Previous Close
    3.2400 / 3.1700
  • Day Range
    Low 3.1500
    High 3.2899
  • 52 Week Range
    Low 3.0700
    High 8.8000
  • Volume
    15,549
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.17
TimeVolumeLNSR
09:32 ET2083.24
10:15 ET6043.15
10:38 ET9003.2
10:49 ET29753.2
11:05 ET2603.2028
11:32 ET1003.2
11:38 ET1273.2
11:39 ET1003.1923
11:54 ET1003.1923
12:12 ET1003.175
12:30 ET2003.185
12:46 ET5003.2
12:51 ET1003.18
12:53 ET2003.18
12:55 ET2003.18
01:15 ET1573.2374
01:18 ET1003.17
01:26 ET8753.2864
01:27 ET2003.17
01:29 ET8753.2866
01:36 ET3003.17
01:44 ET8753.2899
01:45 ET1003.19
01:47 ET21953.18
03:57 ET1003.17
04:00 ET14283.22
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLNSR
LENSAR Inc
34.9M
-1.5x
---
United StatesICAD
ICAD Inc
44.3M
-2.9x
---
United StatesEAR
Eargo Inc
24.1M
-0.1x
---
United StatesSSKN
STRATA Skin Sciences Inc
29.5M
-4.7x
---
United StatesAAXT
Aamaxan Transport Group Inc
20.0
0.0x
---
United StatesQTNT
Quotient Ltd
2.6M
0.0x
---
As of 2022-12-06

Company Information

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The Company is also developing an integrated cataract treatment system, ALLY Adaptive Cataract Treatment System (ALLY). The ALLY system is designed to combine its existing femtosecond laser technology and a phacoemulsification system into a single unit that allows surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

Contact Information

Headquarters
2800 Discovery Drive, Suite 100ORLANDO, FL, United States 32826
Phone
---
Fax
302-655-5049

Executives

Independent Chairman of the Board
William Link
Chief Executive Officer, Director
Nicholas Curtis
Chief Financial Officer, Secretary
Thomas Staab
Chief Operating Officer
Alan Connaughton
Independent Director
Richard Lindstrom

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$34.9M
Revenue (TTM)
$36.3M
Shares Outstanding
11.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.15
Book Value
$4.99
P/E Ratio
-1.5x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
---
Operating Margin
-59.08%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.